转移性去势抵抗性前列腺癌患者三示踪剂PET显像确定的患者内转移灶间异质性及其与生存的相关性:3TMPO队列研究
这项多中心前瞻性观察研究对mCRPC患者行18F-FDG与68Ga-PSMA-617 PET/CT,必要时加做68Ga-DOTATATE PET/CT,发现82.7%存在患者内转移灶间异质性,53.1%符合PSMA放射性配体治疗条件,无人符合DOTATATE治疗条件;存在异质性者中位总生存显著更短(9.5个月 vs 未达到;HR 2.7,95%CI 1.1-6.8)。
要点
- mCRPC患者中患者内转移灶间异质性(IIH)发生率为82.7%。
- 53.1%符合PSMA放射性配体治疗条件,无人符合DOTATATE放射性配体治疗条件。
- 存在IIH者中位总生存显著短于无IIH者(9.5个月 vs 未达到;HR 2.7)。
核心结论
- 大多数mCRPC患者存在患者内转移灶间异质性,且该异质性与更短的总生存相关。
- 基于三示踪剂PET方法观察到多种病灶显像表型组合,这些表型与基因组学及治疗反应的相关性对精准医学有意义。
研究设计与样本
- 多中心前瞻性观察研究,mCRPC患者接受18F-FDG与68Ga-PSMA-617 PET/CT;若发现18F-FDG阳性/68Ga-PSMA阴性病灶,则加做68Ga-DOTATATE PET/CT。
主要发现
- 81例患者(82.7%)观察到患者内转移灶间异质性。
- 45例患者(45.9%)发现至少1个18F-FDG阳性/68Ga-PSMA阴性病灶。
- 在37例同时接受68Ga-DOTATATE PET/CT的参与者中,6例(16.2%)有至少1个68Ga-DOTATATE阳性病灶。
- 共观察到12种不同的病灶显像表型组合。
- 存在IIH的患者中位总生存显著短于无IIH患者(9.5个月 vs 未达到;log-rank P=0.03;HR 2.7;95%CI 1.1-6.8)。
关键数值与推荐
- 每种示踪剂的病灶阳性定义为摄取至少高于肝脏50%。
- 患者内转移灶间异质性定义为在多示踪剂PET上至少2个病灶具有不一致特征的参与者百分比。
- 根据预设标准,52例(53.1%)参与者符合PSMA放射性配体治疗条件,无人符合DOTATATE放射性配体治疗条件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to determine the prevalence of IIH and RPT eligibility in mCRPC patients through a triple-tracer PET imaging strategy. Methods: This was a multisite prospective observational study in which mCRPC patients underwent both 18F-FDG and 68Ga-prostate-specific membrane antigen (PSMA)-617 PET/CT scans. A third scan with 68Ga-DOTATATE, a potential biomarker of neuroendocrine differentiation, was performed if an 18F-FDG-positive/68Ga-PSMA-negative lesion was found. Per-tracer lesion positivity was defined as having an uptake at least 50% above that of the liver. IIH prevalence was defined as the percentage of participants having at least 2 lesions with discordant features on multitracer PET. Results: IIH was observed in 81 patients (82.7%), and at least 1 18F-FDG-positive/68Ga-PSMA-negative lesion was found in 45 patients (45.9%). Of the 37 participants who also underwent 68Ga-DOTATATE PET/CT, 6 (16.2%) had at least 1 68Ga-DOTATATE-positive lesion. In total, 12 different combinations of lesion imaging phenotypes were observed. On the basis of our prespecified criteria, 52 (53.1%) participants were determined to be eligible for PSMA RPT, but none for DOTATATE RPT. Patients with IIH had a significantly shorter median overall survival than patients without IIH (9.5 mo vs. not reached; log-rank P = 0.03; hazard ratio, 2.7; 95% CI, 1.1-6.8). Conclusion: Most mCRPC patients showed IIH, which was associated with shorter overall survival. On the basis of a triple-tracer PET approach, multiple phenotypic combinations were found. Correlation of these imaging phenotypes with genomics and treatment response will be relevant for precision medicine.
引用
- Pouliot F, Saad F, Rousseau E, et al. Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study. J Nucl Med. 2024. PMID: 39327017. doi:10.2967/jnumed.124.268020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。